After losing a couple of pharma alliances in recent quarters, CytomX Therapeutics is getting a major lift from a key collaborator.
After losing a couple of pharma alliances in recent quarters, CytomX Therapeutics is getting a major lift from a key collaborator.
Regeneron is doubling down …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Can the company that shaped cancer treatment reinvent itself?
Novo underwhelmed by drug it once fought Pfizer for
How Poolbeg Pharma could unlock immunotherapy's biggest problem
With Cencora pact, Gilead looks to grow CAR-T treatment center network
Will Makary's FDA voucher program survive?
As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a…
CellCentric has reeled in a $220 million Series D to help it address multiple myeloma patients who have exhausted all other…
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™…
Regeneron Pharmaceuticals has signed a $2.32bn deal with Parabilis Medicines to develop therapeutic candidates, with a focus on…
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
